Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan
- PMID: 29398641
- PMCID: PMC5902408
- DOI: 10.1016/S1474-4422(18)30026-7
Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan
Abstract
Improvements in the function, quality of life, and longevity of patients with Duchenne muscular dystrophy (DMD) have been achieved through a multidisciplinary approach to management across a range of health-care specialties. In part 3 of this update of the DMD care considerations, we focus on primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Many primary care and emergency medicine clinicians are inexperienced at managing the complications of DMD. We provide a guide to the acute and chronic medical conditions that these first-line providers are likely to encounter. With prolonged survival, individuals with DMD face a unique set of challenges related to psychosocial issues and transitions of care. We discuss assessments and interventions that are designed to improve mental health and independence, functionality, and quality of life in critical domains of living, including health care, education, employment, interpersonal relationships, and intimacy.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Figures
Comment in
-
Evidence-based care in Duchenne muscular dystrophy.Lancet Neurol. 2018 May;17(5):389-391. doi: 10.1016/S1474-4422(18)30115-7. Lancet Neurol. 2018. PMID: 29656735 No abstract available.
Similar articles
-
Primary Care and Emergency Department Management of the Patient With Duchenne Muscular Dystrophy.Pediatrics. 2018 Oct;142(Suppl 2):S90-S98. doi: 10.1542/peds.2018-0333K. Pediatrics. 2018. PMID: 30275253
-
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.Lancet Neurol. 2018 Mar;17(3):251-267. doi: 10.1016/S1474-4422(18)30024-3. Epub 2018 Feb 3. Lancet Neurol. 2018. PMID: 29395989 Free PMC article. Review.
-
Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.Lancet Neurol. 2018 Apr;17(4):347-361. doi: 10.1016/S1474-4422(18)30025-5. Epub 2018 Feb 3. Lancet Neurol. 2018. PMID: 29395990 Free PMC article. Review.
-
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.Lancet Neurol. 2010 Jan;9(1):77-93. doi: 10.1016/S1474-4422(09)70271-6. Epub 2009 Nov 27. Lancet Neurol. 2010. PMID: 19945913 Review.
-
Psychosocial Management of the Patient With Duchenne Muscular Dystrophy.Pediatrics. 2018 Oct;142(Suppl 2):S99-S109. doi: 10.1542/peds.2018-0333L. Pediatrics. 2018. PMID: 30275254
Cited by
-
PTPN1/2 inhibition promotes muscle stem cell differentiation in Duchenne muscular dystrophy.Life Sci Alliance. 2024 Oct 30;8(1):e202402831. doi: 10.26508/lsa.202402831. Print 2025 Jan. Life Sci Alliance. 2024. PMID: 39477543 Free PMC article.
-
Characterization of patients with Duchenne muscular dystrophy across previously developed health states.PLoS One. 2024 Oct 30;19(10):e0307118. doi: 10.1371/journal.pone.0307118. eCollection 2024. PLoS One. 2024. PMID: 39475941 Free PMC article.
-
Transition and management of patients with Duchenne Muscular Dystrophy: a narrative review based on Italian experts' opinion and real-world experience.Acta Myol. 2024 Sep;43(3):102-107. doi: 10.36185/2532-1900-447. Acta Myol. 2024. PMID: 39468966 Free PMC article. Review.
-
Gene therapy for Duchenne Muscular Dystrophy: assessing the readiness of Italian centres of expertise.Acta Myol. 2024 Sep;43(3):95-101. doi: 10.36185/2532-1900-487. Acta Myol. 2024. PMID: 39468965 Free PMC article.
-
Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy.Sci Rep. 2024 Oct 8;14(1):23488. doi: 10.1038/s41598-024-70783-y. Sci Rep. 2024. PMID: 39379403 Free PMC article. Clinical Trial.
References
-
- Bushby K, Finkel R, Birnkrant DJ, et al. for the DMD Care Considerations Working Group Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77–93. - PubMed
-
- Bushby K, Finkel R, Birnkrant DJ, et al. for the DMD Care Considerations Working Group Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9:177–89. - PubMed
-
- Saito T, Kawai M, Kimura E, et al. Study of Duchenne muscular dystrophy long-term survivors aged 40 years and older living in specialized institutions in Japan. Neuromuscul Disord. 2017;27:107–14. - PubMed
-
- Medical Home Initiatives for Children With Special Needs Project Advisory Committee, American Academy of Pediatrics. The medical home. Pediatrics. 2002;110(1 Pt 1):184–86. - PubMed
-
- Homer CJ, Klatka K, Romm D, et al. A review of the evidence for the medical home for children with special health care needs. Pediatrics. 2008;122:e922–37. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

